Auto-injectors Market Regional Analysis:
North American Market Insights
Auto-injectors market in North America is predicted to account for the largest share of 45% by 2035, impelled by the rising investment in the healthcare sector. The ongoing advancements and funding to improve public access to healthcare encourage more people with a variety of medical problems to adopt these personal care tools. In addition, recent developments and competitive strategies such as market expansion, mergers & acquisitions, and product launches have been considered to depict a competitive landscape in this region. For instance, in May 2023, Coherus BioSciences, a leading global biosimilar company, announced the commercial launch of UDENYCA, a single-dose prefilled auto-injector package, in the U.S. market. This pegfilgrastim biosimilar is given the day following chemotherapy to reduce the risk of infection.
The U.S. is augmenting the market with a promising growth trajectory, attributable to the favorable regulatory framework, increasing food poisoning cases, and the expanding biosimilar industry. This scenario is attracting global leaders to participate, escalating engagement in this sector. For instance, in July 2023, Boehringer Ingelheim commercially launched a new autoinjector option for its interchangeable biosimilar to Humira, Cyltezo Pen, in the U.S. marketplace. After gaining FDA approval in May, the company distributed the 40 mg/0.8 mL pre-filled adalimumab-adbm in two-, four-, and six-pack doses.
APAC Market Insights
The APAC auto-injectors market is estimated to be the second largest shareholder during the analyzed timeframe, led by rising advancement in medical technologies. Several government campaigns and initiatives from developing countries such as Japan, China, and India are promoting domestic production and the cultivation of innovative medical devices. On this note, in May 2024, Eisai and Nippon Medac collaboratively launched Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL, and 15mg Pen 0.30mL to treat rheumatoid arthritis patients in Japan. In addition, the rapidly aging population, with various chronic illnesses, in these nations are inflating the demand for sophisticated tools that are self-injectable and capable of delivering medications intramuscularly.
India is emerging as a great opportunity for profitable revenue generation for global leaders in the market. There are several factors contributing to the country’s successful propagation in this merchandise: the Make in India campaign, the growing diabetic patient pool, and the accelerating popularity of the remote care approach. In this regard, the Healthcare Federation of India predicted the country’s home healthcare industry to reach USD 19.9 billion by 2025 from USD 5.4 billion in 2022. Additionally, the diabetes population in India is expected to surpass 134.0 million by 2045, as per NLM.
